Another drug that is emerging as potentially therapeutic for PWS symptomatology is diazoxide, an ATP-sensitive K+ channel agonist that inhibits insulin secretion from the pancreas and, thus, modulates insulin-sensitive enzymes, leading to suppressed lipogenesis and increased lipolysis. The gene discussed is INS; the disease is Prader-Willi syndrome.